Navigation Links
Visikol CEO Dr. Michael Johnson Named to 2019 Forbes 30 Under 30 List as a Top Three All Star Alumni

Each year Forbes receives thousands of nominations for candidates wishing to be selected for its annual 30 Under 30 list which highlights outstanding performance by individuals under 30 years of age. The Forbes 30 Under 30 list showcases the top 30 individuals in a wide range of fields from Sports and Entertainment to Venture Capital and Science.

In 2017, Visikol CEO Dr. Michael Johnson was named to the Forbes 30 Under 30 list in the field of Science just after his 27th birthday. Between 2017 and today, Dr. Johnson along with fellow Co-Founder Dr. Tom Villani have taken Visikol from a Rutgers University spin-out to a robust contract research organization business that now provides advanced drug discovery services to the world’s leading pharmaceutical and biotechnology companies. It is due to Visikol’s rapid success and significant market traction that Dr. Johnson was again recognized by Forbes this year on their 2019 30 Under 30 list by being selected among all of the previous year’s honorees as one of the top three all star alumni.

In reflecting on the company’s maturation, Dr. Johnson explains, “From the inception of our company we always had a very clear mission statement which was to develop tools and services to transform tissues into quantitative data sets that could be used to better inform the drug discovery process as well as one day clinical diagnosis. It has been incredible to see this mission statement come to life and in a short period of time improve several drug discovery programs as well as bring to market one of first clinical machine learning digital pathology platforms with Enzyvant Therapeutics.”

To live up to this mission statement, Visikol has placed a large focus on developing not only advanced imaging techniques for acquiring more complete data sets from tissues, but also a suite of digital pathology, machine learning and informatic tools. Combined, this suite of technologies allows Visikol to generate huge quantities of data from tissues and convert the data into simple and easy-to-interpret reports so that pharmaceutical clients can easily make more informed decisions about their drug discovery programs.

Today, Visikol acts primarily as a contract research organization with a specialty in 3D tissue imaging via confocal or light sheet microscopy, digital pathology, 3D cell culture assays, high content screening and custom drug discovery projects. Visikol’s clients work with them in several different ways from sending compounds or antibodies for end-to-end in vitro or in vivo testing to sending histology glass slides for slide scanning and unbiased machine learning analysis.

In describing what makes Visikol successful, Dr. Johnson explains, “There is huge opportunity to disrupt the pathology and imaging fields which we are taking advantage of through providing a quantitative approach to studying tissues. As we grow over the next few years, we are going to continue to develop our technology platform as well as integrate cutting-edge technologies that allow us to offer enhanced services to our clients”

About Visikol
Visikol is a contract research organization that is focused on accelerating drug discovery through the transformation of tissues into actionable and quantitative insights. Visikol is comprised of experts in imaging, digital pathology, machine learning and advanced in vitro models. The company leverages this expertise along with a portfolio of proprietary imaging and image analysis technologies to offer pharmaceutical/biotech companies 3D cell culture assays, digital pathology services, 3D tissue imaging services, high content screening and customized drug discovery solutions. Visikol partners closely with clients in drug discovery efforts and to assist them with using innovative assays for drug screening that are more rapid, reliable, and relevant for screening. In addition to this service offering, Visikol also sells various tissue clearing reagents and kits for researchers that are interested in adopting 3D tissue imaging into their own workflows. For more information about Visikol or its services, please visit our website at

Read the full story at

Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved

Related biology technology :

1. Visikol Machine Learning Digital Pathology Services for Drug Discovery
2. Dr. Michael Johnson, CEO and Co-founder of Visikol, Invited to Speak with Governor Murphy on Behalf of the Science, Innovation, and Technology Commission Bill
3. Drs. Richard Amato and Michael Kang Improve Bone Grafts, Dental Implants and Tooth Extractions in Danbury, CT with Modern Technology
4. Periodontist Michael Hoge, DMD; MS of Precision Periodontics and Implant Dentistry Now Offers LANAP Laser Treatment for Gum Disease
5. Former VP of Clinical Pharmacology at Nektar Therapeutics, Michael A. Eldon, PhD, FCP, Joins NDA Partners as Expert Consultant
6. Slone Partners Hosts Precision Medicine Event Led by Michael Pellini, MD with Panelists Troy Cox, Barbara Weber, MD and Roman Yelensky, PhD
7. Inhibikase Awarded $433,000 from The Michael J. Fox Foundation to Advance Development of Kinase Inhibitor Treatment for Parkinsons Disease
8. Dr. Michael A. Pfaller of T2 Biosystems to Discuss the Vital Role of Transformative Diagnostics in Optimizing Antimicrobial Stewardship in New Webinar
9. Arizona Hand Surgeon Dr. Michael Fitzmaurice Double Board-Certified in Surgery and Surgery of the Hand
10. Recruitment Process Outsourcing (RPO) Market Heats Up Faster as Accolo Hires RPO Heavyweight Michael Palmer
11. Bantam Pharmaceutical Appoints Dr. Michael Luther President and CEO
Post Your Comments:
(Date:4/25/2019)... ... April 24, 2019 , ... Inference Solutions ... service organizations, today announced global availability of Inference Studio’s latest version, which makes ... sizes to harness the power of Google’s Contact Center AI (CCAI). ...
(Date:4/15/2019)... ... April 15, 2019 , ... Sirrus, ... a $2 million bench plant expansion to increase production of methylene malonate monomers ... design and construction of Sirrus’ full-scale production facility, which is scheduled to break ...
(Date:4/9/2019)... ... 09, 2019 , ... USDM Life Sciences , the ... organizations to accelerate innovation and maximize productivity, announces that nearly 100 companies have ... , USDM’s Cloud Assurance is a managed subscription service delivering end-to-end ...
(Date:4/8/2019)... ... April 08, 2019 , ... US Capital Global ... $15 million preferred equity investment in the privately held pharmaceutical company, S1 Biopharma (“S1”). ... Lorexys, is targeted at female hypoactive sexual dysfunction disorder and is ready to begin ...
Breaking Biology Technology:
(Date:5/21/2019)... ... May 21, 2019 , ... Suvoda LLC , a SaaS provider ... has been named one of Inc. Magazine’s Best Workplaces for 2019, Inc.’s fourth annual ... featured on and hitting the newsstands on May 28, is the result of ...
(Date:5/21/2019)... BOSTON (PRWEB) , ... May 21, 2019 , ... At ... Engineered Constructs for Tissue Engineered Medical Products (TEMPs) of the American Society for ... Asymmetrex . Gaining this approval was the next step in the company’s ...
(Date:5/14/2019)... Calif. (PRWEB) , ... May 13, 2019 , ... ... on Tuesday, June 4th, at a very special Pre-EWMA 2019 event at Gothenburg’s ... on the latest Trends, Opportunities and Innovations in Advanced Wound Care. , SmartTRAK’s ...
Breaking Biology News(10 mins):